(1S)-1-cyclopropyl-2-[(2S)-4-(2,5-difluorophenyl)-2-phenyl-2,5-dihydro-1H-pyrrol-1-yl]-2-oxoethanamine

This compound is a cyclopropyl-fused pyrrolidine derivative designed as an inhibitor of dipeptidyl peptidase IV (DPP-IV or DPP4), an enzyme involved in the degradation of incretin hormones such as GLP-1. Inhibition of DPP-IV increases endogenous levels of these hormones, thereby enhancing insulin secretion and lowering blood glucose. Such compounds are primarily developed for the treatment of type 2 diabetes mellitus. The structure features a cyclopropyl group fused to a pyrrolidine ring with difluorophenyl and phenyl substituents, conferring selectivity and potency for the DPP-IV target[1][7]. No evidence was found that this specific compound has reached clinical development or been marketed.

Other names

cyclopropyl-fused pyrrolidine-based DPP-IV inhibitor